02066nas a2200289   4500000000100000008004100001260001200042653000800054653000800062653001500070653001500085653001200100653002200112100001000134700001300144700001500157700001600172700001500188700001200203700001300215245006200228856008000290300001100370490000600381520137500387022001401762       2021                            d  c01/202110aENL10aT1R10abiomarkers10acorrelates10aleprosy10aleprosy reactions1 aLuo Y1 aKiriya M1 aTanigawa K1 aKawashima A1 aNakamura Y1 aIshii N1 aSuzuki K00aHost-Related Laboratory Parameters for Leprosy Reactions.  uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8568883/pdf/fmed-08-694376.pdf  a6943760 v83 a<p>Leprosy reactions are acute inflammatory episodes that complicate the course of a infection and are the major cause of leprosy-associated pathology. Two types of leprosy reactions with relatively distinct pathogenesis and clinical features can occur: type 1 reaction, also known as reversal reaction, and type 2 reaction, also known as erythema nodosum leprosum. These acute nerve-destructive immune exacerbations often cause irreversible disabilities and deformities, especially when diagnosis is delayed. However, there is no diagnostic test to detect or predict leprosy reactions before the onset of clinical symptoms. Identification of biomarkers for leprosy reactions, which impede the development of symptoms or correlate with early-onset, will allow precise diagnosis and timely interventions to greatly improve the patients' quality of life. Here, we review the progress of research aimed at identifying biomarkers for leprosy reactions, including its correlation with not only immunity but also genetics, transcripts, and metabolites, providing an understanding of the immune dysfunction and inflammation that underly the pathogenesis of leprosy reactions. Nevertheless, no biomarkers that can reliably predict the subsequent occurrence of leprosy reactions from non-reactional patients and distinguish type I reaction from type II have yet been found.</p>
  a2296-858X